Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 7
- Registration Number
- NCT03287674
- Locations
- ๐ฉ๐ฐ
Center for Cancer Immune Therapy Dept. of Hematology/oncology, Copenhagen, Denmark
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Greg Durm, MD
- Target Recruit Count
- 105
- Registration Number
- NCT03285321
- Locations
- ๐บ๐ธ
Penn State Cancer Institute, Hershey, Pennsylvania, United States
๐บ๐ธJohns Hopkins Sidney Kimmel Comprehensive, Baltimore, Maryland, United States
๐บ๐ธMichigan State University, Lansing, Michigan, United States
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03283046
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT03274258
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
- Conditions
- Interventions
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 75
- Registration Number
- NCT03271047
- Locations
- ๐บ๐ธ
Washington University School of Medicine, Saint Louis, Missouri, United States
๐บ๐ธSiteman Cancer Center - South County, Saint Louis, Missouri, United States
๐ช๐ธHospital Universitario Vall d'Hebrรณn - PPDS, Barcelona, Spain
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
- Conditions
- Interventions
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT03256136
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธMassachusetts general Hospital, Boston, Massachusetts, United States
Nivolumab Plus Ipilimumab in Thyroid Cancer
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 53
- Registration Number
- NCT03246958
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03245892
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Incyte Biosciences International Sร rl
- Target Recruit Count
- 52
- Registration Number
- NCT03241173
- Locations
- ๐บ๐ธ
The University of Alabama Birmingham (UAB), Birmingham, Alabama, United States
๐บ๐ธMount Sinai Medical Center of Florida, Inc., Miami, Florida, United States
๐บ๐ธThe Angeles Clinic and Research Institute, Los Angeles, California, United States
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Robert R. McWilliams, MD
- Target Recruit Count
- 36
- Registration Number
- NCT03241186
- Locations
- ๐บ๐ธ
Mayo Clinic Rochester, Rochester, Minnesota, United States
๐บ๐ธNebraska Cancer Specialists, Omaha, Nebraska, United States
๐บ๐ธUniversity of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.